BIOTON S.A. (BIO) AI Stock Analysis

• Market Cap: zł358.91M
• Dividend Yield: N/A
• Average Volume (3M): 33.62K
• Price to Earnings (P/E): 97.7
• Beta (1Y): 0.21
• Revenue Growth: 42.31%
• EPS Growth: -51.82%
• Country: PL
• Employees: 361
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.02
• Shares Outstanding: 85,864,200
• 10 Day Avg. Volume: 22,695
• 30 Day Avg. Volume: 33,619
• PEG Ratio: -0.80
• Price to Book (P/B): 0.56
• Price to Sales (P/S): 1.17
• P/FCF Ratio: 145.62
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.14
• Revenue Forecast (FY): zł266.00M

• Rating: 56 Neutral
• Price Target: zł4.50 ▲(10.57% Upside)
• Action: Reiterated Date: 09/28/25
• Date: Action: Reiterated 09/28/25

The overall stock score is driven by mixed financial performance and positive technical indicators. Strong revenue growth and stable balance sheet are offset by declining profitability and negative net income. Technical analysis shows bullish momentum, but valuation concerns due to negative P/E ratio and lack of dividend yield weigh on the score.

BIOTON S.A. Business Overview & Revenue Model

Company Description

BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceuticals, pharmaceutical preparations, pharmaceutical substances, medications, and other pharmaceutical products in Poland, China, Thailand, Vietnam, Libya, Argentina, Ukraine, Malta, Yemen, and the Russian Federation. The company offers recombinant human and classic insulin; oral anti-diabetic medication products; dietary supplements; strips for measuring sugar in blood, as well as OTC preparation for diabetics; diabetics drugs insulin vials and cartridges, including Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes monitoring technology, as well as needles. It engages in advertising, advisory, and company management activities. The company was founded in 1989 and is based in Ozarów Mazowiecki, Poland.

How the Company Makes Money

BIOTON generates revenue through several key streams, primarily from the sale of its insulin products and biosimilars, which are marketed in various countries. The company has established partnerships with international pharmaceutical companies, enabling it to expand its distribution networks and enhance its market reach. Additionally, BIOTON may earn revenue from licensing agreements and collaborations in research and development, which can provide upfront payments as well as royalties on future sales. The company's strategic focus on high-demand therapeutic areas, combined with its innovative product pipeline, contributes significantly to its earnings.

BIOTON S.A. Financial Statement Overview

Summary

BIOTON S.A. shows mixed financial performance. Strong revenue growth is overshadowed by declining profitability margins and negative net income. The balance sheet is stable with low leverage, but negative returns on equity indicate inefficiencies. Cash flow generation has improved, yet operational cash flow remains a concern.

Income Statement

The company has shown a significant revenue growth rate of 16.99% in the latest year, indicating a positive trajectory. However, the gross profit margin has decreased from 40.11% to 31.21%, and the net profit margin has turned negative at -7.54%, reflecting challenges in maintaining profitability. The EBIT margin is also negative, indicating operational inefficiencies.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.096, suggesting a conservative leverage approach. However, the return on equity is negative at -2.65%, indicating inefficiencies in generating returns for shareholders. The equity ratio remains stable, showing a solid capital structure.

Cash Flow

The free cash flow has grown significantly by 145.48%, indicating improved cash generation capabilities. However, the operating cash flow to net income ratio is low at 0.25, suggesting that cash generation from operations is not fully supporting net income. The free cash flow to net income ratio is positive, indicating some level of cash profitability.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	282.52M	207.76M	181.64M	233.16M	163.03M
Gross Profit	91.80M	64.84M	72.85M	95.75M	76.32M
EBITDA	52.89M	32.57M	31.26M	58.56M	45.09M
Net Income	3.39M	-15.66M	2.27M	1.42M	2.88M
Balance Sheet
Total Assets	764.56M	794.14M	822.22M	810.33M	865.19M
Cash, Cash Equivalents and Short-Term Investments	8.28M	6.96M	3.88M	9.34M	8.86M
Total Debt	57.16M	56.57M	68.69M	76.39M	110.08M
Total Liabilities	170.59M	203.59M	215.87M	204.27M	242.45M
Stockholders Equity	593.97M	590.55M	606.36M	606.06M	604.51M
Cash Flow
Free Cash Flow	2.28M	24.72M	-4.54M	26.50M	-7.37M
Operating Cash Flow	15.34M	36.33M	39.63M	56.08M	5.52M
Investing Cash Flow	-13.01M	-11.61M	-36.95M	-29.10M	-4.28M
Financing Cash Flow	-1.01M	-21.64M	-8.13M	-26.50M	-14.62M

BIOTON S.A. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.07
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:BIO, the sentiment is Negative. The current price of 4.07 is below the 20-day moving average (MA) of 4.19, below the 50-day MA of 4.09, and below the 200-day MA of 4.16, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 46.42 is Neutral, neither overbought nor oversold. The STOCH value of 57.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PL:BIO.

BIOTON S.A. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SLV	59 Neutral	zł679.15M	-187.28	-1.25%	―	14.10%	-99.00%
BIO	56 Neutral	zł358.91M	97.68	-1.76%	―	42.31%	-51.82%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MAB	46 Neutral	zł147.56M	-3.23	-59.73%	―	-74.16%	-192.42%
CTX	44 Neutral	zł443.16M	-4.87	-109.96%	―	-40.45%	27.53%
RVU	38 Underperform	zł539.86M	-6.32	-110.42%	―	15.45%	-25.81%